In addition, clinical trials on the FDA-approved CD19 CAR-T cells for PCNSL and secondary CNS lymphoma are ongoing (NCT04134117, NCT04608487, NCT03484702) [29]. The gene discussed is CD19; the disease is primary central nervous system lymphoma.